Description

Cencora’s U.S. Healthcare Business Is Surging—How Did It Raise Guidance Despite Losing a Major Customer?

Cencora’s fiscal 2026 first-quarter results illustrate both strengths and challenges within the company’s operational and strategic landscape. The completion of Cencora’s acquisition of the remaining equity interest in OneOncology stands out as a significant milestone, underlining the company’s commitment to expanding its presence and capabilities within the specialty pharmaceutical supply chain. From an earnings perspective, Cencora reported a 9% growth in adjusted diluted earnings per share and a 12% increase in adjusted operating income, alluding to a successful quarter driven by its U.S. Healthcare Solutions business. The segment buoyed the company’s performance, contributing to a revenue of $85.9 billion, marking a 5.5% increase from the prior year. Particularly, sales of GLP-1 products in the U.S. were strong, increasing by 11% compared to the same quarter last year.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!